Oral Tranexamic Acid After Total Knee Arthroplasty
ConditionTotal Knee Arthroplasty
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorRush University Medical Center
About this trial
This is a prospective, double-blind, randomized controlled trial evaluating the efficacy of oral tranexamic acid (TXA) in total knee arthroplasty (TKA). The study will assess pain, function, and range of motion (ROM) over a 2-year period, with key evaluations at 6 weeks and 90 days postoperatively.
Hypothesis:
Patients receiving 1.95g oral TXA for 3 or 7 days post-op will show improved pain, function, and ROM at 6 weeks and 90 days, with similar blood loss and transfusion rates as the control group.
Eligibility criteria
Qualifiers
Any patient undergoing primary TKA at Rush main hospital or participating ASC
Willingness to undergo randomization to take medication potentially up to 7 days post op.
Willing to answer daily questions on pain, functionality and opioid consumption
Disqualifiers
History of venous thromboembolism, MI, or stroke in the past year
Patients on any chronic anticoagulation medications besides Aspirin
Patients with Cancer
Patients with end stage renal disease that are on dialysis
Trial design
Treatments tested in this trial
- tranexamic acid Oral-Short Arm
- tranexamic acid Oral-Long Arm
- Control group placebo
Treatment groups
351 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov